Literature DB >> 15636679

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

Nancy Price, Robert Dreicer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15636679     DOI： 10.1016/s1540-0352(11)70076-2

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN： 1540-0352


× No keyword cloud information.
  6 in total

1.  Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Authors:  P J Paul; D Raghu; A-L Chan; T Gulati; L Lambeth; E Takano; M J Herold; J Hagekyriakou; R L Vessella; C Fedele; M Shackleton; E D Williams; S Fox; S Williams; S Haupt; C Gamell; Y Haupt
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

2.  The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.

Authors:  Frank Pajonk; Arndt van Ophoven; Christian Weissenberger; William H McBride
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

3.  High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.

Authors:  S G Zhao; W C Jackson; V Kothari; M J Schipper; N Erho; J R Evans; C Speers; D A Hamstra; Y S Niknafs; P L Nguyen; E M Schaeffer; A E Ross; R B Den; E A Klein; R B Jenkins; E Davicioni; F Y Feng
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-19       Impact factor: 5.554

4.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22

Review 5.  Current perspectives in the treatment of advanced prostate cancer.

Authors:  Victor Valdespino; Panagiotis Tsagozis; Pavel Pisa
Journal:  Med Oncol       Date:  2007       Impact factor: 3.738

6.  Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.

Authors:  J-S Diallo; B Betton; N Parent; B Péant; L Lessard; C Le Page; R Bertrand; A-M Mes-Masson; F Saad
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.